Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Item

http://www.wikidata.org/entity/Q34730962

Q34730962

about

Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial New and emerging disease modifying therapies for multiple sclerosis Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7 Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Newer therapies for multiple sclerosis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Multiple sclerosis-a quiet revolution Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis The mechanism of action of interferon-β in relapsing multiple sclerosis Interferons at age 50: past, current and future impact on biomedicine History of modern multiple sclerosis therapy Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology Interferon-β-1b: a review of its use in multiple sclerosis Pulmonary arterial hypertension associated with interferon therapy: a population-based study Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives Hypnosis for pain and neuromuscular rehabilitation with multiple sclerosis: case summary, literature review, and analysis of outcomes.A robust mixed linear model analysis for longitudinal data.Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.Issues and practices in multiple sclerosis.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study.Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.Imaging of multiple sclerosis: role in neurotherapeutics.MRI to monitor treatment efficacy in multiple sclerosis.[Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.Proton magnetic resonance spectroscopy in multiple sclerosis.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Multiple sclerosis lesions: insights from imaging techniques.Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis

P2860

Q21203734-A1D46718-812A-436F-9D31-6E1649A1B234 Q22242305-BDF7CCDF-D04E-436C-960A-59ED9578CEE7 Q22252598-39F51922-967D-497D-8128-EC1DF9D9F7AF Q22254705-75C6D3E3-7C9F-4E72-B17F-0073C3CE1722 Q24597369-7CE87A77-3278-47C1-A323-8557DF25BD83 Q24652353-B8902115-873E-4E11-98F6-E487E1FECF1C Q26745562-D6B88D76-0756-414E-893D-4CEA3678B6D7 Q26752859-52B55D75-5343-4498-81F2-7FD26D3C35C9 Q26770664-18BA396D-8E7F-4C2F-9563-89ACE8BBC7BA Q26779900-0D3DE018-2F62-4791-BF0F-5BAE59FD802B Q26798434-B1A49836-1EA9-4ECD-8B81-74C400E1E320 Q26822611-024C3B4B-A234-4AAC-8B53-95842A024D6F Q26826930-CC336225-CFC5-4F71-A28D-9336C77FE300 Q26852672-7E1E7C67-31E6-4226-954B-7D0C6C4008A8 Q27004079-6678669A-98D1-493C-A9E2-068430F856FF Q27693249-DFABA3DE-B626-4204-A9F9-C072D80C71B0 Q28239752-FA0BF440-5282-4B7A-AA11-CE6688FCE23A Q28259312-C0BB58FA-DD34-4CFB-B5CB-8B66C52A5334 Q28273033-E4FABCDA-48A8-472A-95A3-64BCF1B47F18 Q28277470-502013CD-03B3-47C4-A7B7-C88213984659 Q28299160-23CB0080-A5C2-459B-B364-02FF42D21D47 Q28299838-1B18C8A8-11F6-47F3-8390-2A8D53F1ECAB Q28468304-587576BC-7E2B-437C-819A-C138C41E7BC4 Q28478190-5CADB686-CA8E-4C84-941A-7E96DF7A3D07 Q29030703-7FF0DFA4-CF3F-4E1E-9832-28023860D6CB Q30468648-BBA56661-1E5C-4523-B31F-FE1279BA4FED Q30588811-D479D892-12C1-4F8F-8403-DA7156315118 Q30691743-DD79ADD5-E407-46C2-8309-851C1C2FC420 Q30751454-82FA54C7-A32A-428D-95D7-5DBBCECBD263 Q30869048-5E372005-4030-4DA8-AAD9-E5E97018C14F Q30928115-873436D1-BD4A-49C8-97C5-F052BBD5E457 Q30983016-4B9BEBD4-CCD0-4C4B-9622-7E5FCD61399C Q30989935-0A234A0D-FD23-44EB-A7EC-4813649BBD8D Q31108872-FC199EAC-58A5-4666-8BB0-7FBD60A8F880 Q31149165-6769FB6C-4B04-4511-B12E-749881197E87 Q32091527-6B38099F-7E5D-43EB-BA7D-86CC5D5BC01D Q33390863-1A4E0344-26B7-4547-842D-9CECEB0FE560 Q33500910-5530EC73-6406-458D-8D90-C7E183DB96C8 Q33505423-9DCA74EE-0178-4126-B64C-19472D5C473C Q33572798-005CFAA4-1698-4B5B-8542-3FE5D805A53E

P2860

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Item

http://www.wikidata.org/entity/Q34730962

description

1993 nî lūn-bûn

@nan

1993 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu